Dose escalation for prostate cancer radiotherapy: Predictors of long-term biochemical tumor control and distant metastases-free survival outcomes

European Urology

Volumn 60, Issue 6, 2011, Pages 1133-1139

  Zelefsky, Michael J ^a   Pei, Xin ^a   Chou, Joanne F ^a   Schechter, Michael ^a   Kollmeier, Marisa ^a   Cox, Brett ^a   Yamada, Yoshiya ^a   Fidaleo, Anthony ^a   Sperling, Dahlia ^a   Happersett, Laura ^a   Zhang, Zhigang ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androgen deprivation therapy; Dose escalation; External beam radiotherapy; Prostate cancer; PSA relapse free survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RETROSPECTIVE STUDY; TUMOR BIOPSY;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEW YORK CITY; NOMOGRAMS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80255136257     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.08.029     Document Type: Article

References (20)

1. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105 (Pubitemid 34787842)
2. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 2010 1106 1111
3. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996 (Pubitemid 46622106)
4. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487 (Pubitemid 46805903)
5. D.A. Kuban, L.B. Levy, and M.R. Cheung Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: who dies of disease? Int J Radiat Oncol Biol Phys 79 2011 1310 1317
6. M.J. Zelefsky, H. Chan, M. Hunt, Y. Yamada, A.M. Shippy, and H. Amols Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer J Urol 176 2006 1415 1419 (Pubitemid 44307191)
7. M.J. Zelefsky, M.W. Kattan, and P. Fearn Pretreatment nomogram predicting ten-year biochemical outcome for three-dimeniosnal conformal radiotherapy and intensity modulated radiotherapy for prostate cancer Urology 70 2007 283 287 (Pubitemid 47362254)
8. Z.A. Alickus, Y. Yamada, and Z. Zhang Ten year outcomes of high dose, intensity modulated radiotherapy for localized prostate cancer Cancer 117 2011 1429 1437
9. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500 (Pubitemid 28275076)
10. M. Gönen, and G. Heller Concordance probability and discriminatory power in proportional hazards regression Biometrika 92 2005 965 970 (Pubitemid 41681247)
11. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Statistical Assoc 94 1999 496 509
12. R.G. Stock, J.A. Cesaretti, S.J. Hall, and N.N. Stone Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy BJU Int 104 2009 1631 1636
13. Fang LC, Merrick GS, Butler WM, et al. High-risk prostate cancer with Gleason score 8-10 and PSA level <15 ng/ml treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. In press.
14. I. Deutsch, M.J. Zelefsky, and Z. Zhang Comparison of PSA relapse-free survival in patients treated with ultra-high dose IMRT versus combination HDR brachytherapy and IMRT Brachytherapy 9 2010 313 318
15. A.A. Martinez, J. Gonzalez, and H. Ye Dose escalation improves cancer-related events at 10 years for intermediate and high risk prostate cancer patients treated with hypofractionated high dose rate boost and external beam radiotherapy Int J Radiat Oncol Biol Phys 79 2011 363 370
16. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. DellaCroce, and P.W. Kantoff 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827 (Pubitemid 39079668)
17. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short term androgen deprivation for localized prostate cancer New Engl J Med 365 2011 107 118
18. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer New Engl J Med 360 2009 2516 2527
19. M.J. Zelefsky, E.J. Levin, and M. Hunt Incidence of later rectal and urinary toxicities after three dimensional conformal radiotherapy and intensity modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 15 2008 1124 1129 (Pubitemid 351296130)
20. M.J. Zelefsky, V.E. Reuter, and Z. Fuks Influence of local control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer J Urol 179 2008 1368 1373